Read the full guides
Cardiogen
Last reviewed: July 22, 2026 by The Peptide Catalog Team
A Khavinson cardiac tetrapeptide (Ala-Glu-Asp-Arg / AEDR) studied in review and cell-transport work for a role in cardiovascular inflammaging; preclinical and mechanistic only, no human trials. A Khavinson cardiac peptide bioregulator — the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR) studied in review and cell-transport work for a proposed role in cardiovascular gene regulation. Preclinical and mechanistic only, no human trials.
Overview
Core Benefits
Key AdvantagesThese are educational summaries of commonly discussed effects in wellness/regenerative contexts, not guarantees.
Cardiogen Results Timeline
ProgressionTimeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.
How It WorksKhavinson Peptide Bioregulator — AEDR Tetrapeptide (Preclinical)
Target → Signal → Effect → Outcomes
Gene-Regulatory Regions in Cardiovascular Cells
Cardiogen is the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), part of the Khavinson family of short "peptide bioregulators." The proposed mechanism is epigenetic: short peptides are theorized to enter cells and interact with gene-regulatory regions, modulating tissue-specific gene expression in cardiac and vascular cells. This model is drawn from the broader bioregulator literature, much of it from a single Russian research program.
Proposed Regulation of Cardiovascular Inflammaging (Review-Level)
A 2022 review from the Khavinson group described the AEDR tetrapeptide among peptides that regulate molecules involved in inflammaging and the senescence-associated secretory phenotype (SASP) in cardiovascular-system cells. A 2023 paper modeled how ultrashort peptides are transported into cells. These are mechanistic and review-level findings — not effects demonstrated in tissue, animals, or people.
Theorized Myocardial / Vascular Support
The marketed effect — cardiovascular support and myocardial recovery — is an extrapolation from the peptide's cardiac-tissue origin and its proposed gene-regulatory role. There is no human clinical trial showing Cardiogen improves cardiac function or vascular outcomes, so the systemic effect is hypothesis, not demonstrated outcome.
Unestablished in Humans
Because there is no human efficacy data, there is no documented "felt" effect. Community reports are mixed anecdote. "No noticeable change" is fully consistent with what is currently known about Cardiogen.
What Makes This Peptide Different
Cardiogen belongs to the Khavinson short-peptide bioregulator class, theorized to act as tissue-specific epigenetic signals rather than receptor agonists. What distinguishes Cardiogen is not strength of evidence — it is the opposite: it is marketed for the heart largely on the basis of review-level and cell-transport modeling work and its cardiac-derived sequence, with no human clinical trials behind it.
Cardiogen Vendors
Dosing ProtocolCardiovascular Tissue (preclinical)
Educational reference only. Individual responses vary. Consult healthcare provider before use.
Why This Dosing Protocol
Why short courses? The bioregulator theory holds that brief peptide exposure triggers gene-expression changes that persist after dosing stops — which is convention from the class literature, not a tested Cardiogen protocol.
Reconstitution Calculator
Dilution math and unit conversions. Prefilled using a common vial size for this peptide.
Open calculatorStorage & Handling
Storage at a glance
Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.
Handling specifics
Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.
- Freezer (-20°C): 1+ year
- Refrigerator (2-8°C): 1-3 months
- Room temperature: 2-3 weeks (emergency only)
- MUST refrigerate at 2-8°C
- 4-week maximum shelf life
- NEVER freeze after reconstitution
- Use bacteriostatic water for multi-dose
FAQ
What is Cardiogen?
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg, or AEDR) from the Khavinson family of short "peptide bioregulators." The sequence is associated with cardiac tissue, and it is marketed for cardiovascular and myocardial support. Its proposed mechanism is epigenetic — short peptides entering cells and nudging tissue-specific gene expression. Importantly, the published research is preclinical and mechanistic: review and cell-transport modeling work, almost entirely from a single Russian research group, with no controlled human trials.
How strong is the evidence behind Cardiogen?
Weak. The evidence base is small and preclinical. A 2022 review from the originating group described the AEDR tetrapeptide as a regulator of molecules involved in cardiovascular-cell inflammaging and SASP (Khavinson et al., 2022), and a 2023 paper modeled how ultrashort peptides are transported into cells (Khavinson et al., 2023). There are no human clinical trials, no FDA evaluation, and no large independent replications. Treat it as an early-stage research compound, not a proven therapeutic.
What dose of Cardiogen do people use?
There is no clinical-trial-established human dose. Community and vendor sources describe low-dose subcutaneous courses — commonly a few hundred micrograms to a few milligrams once daily for short 10-20 day courses — extrapolated from the older Khavinson bioregulator practice. These are community conventions, not validated protocols.
Does Cardiogen actually protect the heart in humans?
There is no human clinical trial showing Cardiogen improves cardiac function, protects the myocardium, or changes any cardiovascular outcome. The heart framing comes from the peptide's tissue origin and from review-level gene-expression theory. Any "cardioprotection" claim should be read as theoretical until human data exists.
How long does reconstituted peptide last?
Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.
Is this peptide legal to purchase?
Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.
New to peptides?
Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.
Cardiogen Research Articles
Cardiogen Dosage: Community Protocols Explained
There is no trial-established Cardiogen dose. Community sources cluster around low-dose subcutaneous courses. The reconstitution math, explained.
resultsCardiogen Results: What to Realistically Expect
There is no human timeline data for Cardiogen. What community sources report, why it's mostly theoretical, and how to read it honestly.
guidesCardiogen Reconstitution: 20mg Mixing Chart
A 20mg Cardiogen vial plus 2mL bacteriostatic water gives 10mg/mL. Because community doses are tiny, dilution choice matters. Charts, storage, and steps.
guidesBuy Cardiogen: Price, COA & Cost Per Week
Only 1 vetted Cardiogen source right now: $63.95 a vial, $3.20/mg. Codes save up to 10%. COA status and real cost per week.
Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.